Outlook for Medium-Size Labs Continues to Show Promise

The outlook for the mid-size and smaller publicly traded laboratories appears to be bright. Most reported gains in earnings or revenue, or significant capital infusions in the most recent quarter and … [Read more...]

Troubled Calloway Laboratories Shut Its Doors

Calloway has gone away. The troubled Calloway Laboratories abruptly shut its doors on Oct. 16. The closure of the Woburn, Mass.-based lab put about 240 employees out of work. Calloway Chief Executive … [Read more...]

CardioDx Inks Draw Deal With Quest

CardioDx, a California-based molecular laboratory that specializes in cardiac assays, has entered into a blood draw agreement with national lab giant Quest Diagnostics. Under the terms of the … [Read more...]

Exosome Raises Second Round Funding, Close to Launching Cancer Tests

Exosome Diagnostics has continued on its capital raising roll, bringing in another $17.6 million in financing, and its series B total to $44.7 million. The latest round was funded by Forbion Capital … [Read more...]

Laboratory M&A: Most of the Smaller Players Have Been Absorbed, Leading to Fewer, But Bigger Deals

Fewer deals. Bigger pricetags. That in a nutshell sums up the merger and acquisition activity in the laboratory sector during the first half of 2015. Altogether, there were 10 deals involving labs … [Read more...]

Theranos Strikes Deal With Pennsylvania Insurer; Begins Obtaining FDA Clearances

Upstart laboratory Theranos keeps chugging along, inking its first deal with a major payer and obtaining federal regulatory approval for its unique testing system. The California-based Theranos … [Read more...]

23andMe Raises $79 Million From Undisclosed Investors

23andMe, the California-based lab that has clashed with the Food and Drug Administration over the molecular testing it has offered to the public, has recently raised $79 million from outside … [Read more...]

Cynvenio Raises Capital, Enters Into Pact With Cancer Patient Exchange Firm

Cynvenio Biosystems has raised $35.5 million in second-round private equity funding and has struck an agreement with another company to help place its patients into clinical trials. The funding for … [Read more...]

Quarterly Numbers for Niche Labs Indicate a Maturing Market

As personalized medicine and molecular testing have established themselves in the health care sector, it is leading to more mature growth patterns for the publicly-traded specialty laboratories. … [Read more...]

Foundation Medicine Enters Into Collaborative Agreement with NCI

They’re called “exceptional responders.” They are cancer patients who had an unexpected and long-lived reaction to a form of treatment that few other patients—typically less than 10 … [Read more...]